United States - English - NLM (National Library of Medicine)

vifor (international) inc. - epoetin (unii: 64fs3bfh5w) (epoetin - unii:64fs3bfh5w) - retacrit is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and not on dialysis to decrease the need for red blood cell (rbc) transfusion. retacrit is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with hiv-infection with endogenous serum erythropoietin levels of ≤ 500 munits/ml. retacrit is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. retacrit is indicated to reduce the need for allogeneic rbc transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dl who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. retacrit is not indicated for patients who are willing to donate autologous blood pre-operatively. retacrit has not been shown to improv

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron carboxymaltose - dispersion for injection/infusion - 50 iron milligram(s)/millilitre - iron, parenteral preparations

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor fresenius medical care renal pharma uk ltd - sucroferric oxyhydroxide - chewable tablet - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor fresenius medical care renal pharma france - calcifediol - prolonged-release capsule, soft - 30 microgram(s) - calcifediol; other anti-parathyroid agents